An Open Label, Single Arm, Extension Trial to Examine Long-term Safety of Iclepertin Once Daily in Patients With Schizophrenia Who Have Completed Previous Iclepertin Phase III Trials (CONNEX-X)

Inclusion criteria:

* Signed and dated written informed consent.

* Clinically stable outpatients who have been diagnosed with schizophrenia (as per Diagnostic and Statistical Manual of Mental Disorders 5th Edition (DSM-5)).

* Patients, who completed participation in the parent trial.

* Women of childbearing potential must use highly effective methods of birth control.

* Have a study partner who interacts with the patient on a regular basis. Further inclusion criteria apply.

Exclusion criteria:

* Participant who developed DSM-5 diagnosis other than Schizophrenia or any condition that would prevent the patient from participating in the extension trial since enrolment into the parent phase III trial.

* Any suicidal behavior and/or suicidal ideation of type 5 based on the Columbia Suicidality Severity Rating Scale (C-SSRS) in parent trial and up to and including Visit 1 of this study.

* Positive urine drug screen ≥ 3 times during the treatment period of parent trial.

* Patients who are currently or wish to participate in another investigational drug trial.

* Any clinically significant finding or condition in the judgment of the investigator that would jeopardize the patient´s safety while participating in the trial or their capability to participate in the trial.

Further exclusion criteria apply.